MINNEAPOLIS, Sept. 25, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced its participation in the Craig-Hallum Alpha Select Conference on Thursday, September 27, 2012. David Kaysen, President and CEO, and Medi Jiwani, Chief Financial Officer, will present and meet with investors one on one at the conference in New York City.
Attendance at the conference is by invitation only. The presentation and the meetings will not be webcast.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information:
David Kaysen, President and CEO, or
Doug Sherk/Jenifer Kirtland (Investors), 415.568.9349
Medi Jiwani, Vice President, CFO, Treasurer
Chris Gale (Media), 646.201.5431
SOURCE Uroplasty, Inc.